Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2024-04-11 Regulatory Filings
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Results from XVIVO’s clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague
Regulatory Filings Classification · 95% confidence The document announces the presentation of clinical trial results (NIHP2019) for a medical device (XVIVO Heart Assist Transport) at a scientific meeting (ISHLT). It details key efficacy data (reduction in severe complications and PGD) and includes quotes from the CEO and investigators. Crucially, the document ends with a statement: "This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation," followed by an attachment link to the full results. This structure—a brief announcement summarizing material non-public information required for disclosure under EU regulations, often accompanied by an attachment—strongly suggests a regulatory disclosure intended to inform the market immediately. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is an announcement of material information rather than a specific financial result release (ER), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for mandatory market disclosures that don't fit other specific types, especially those related to operational or clinical milestones under MAR.
2024-04-11 English
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-04 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-04 Swedish
KALLELSE TILL ÅRSSTÄMMA I XVIVO PERFUSION AB (PUBL)
AGM Information Classification · 100% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I XVIVO PERFUSION AB (PUBL)" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)". The text details the date, time, location for registration, requirements for shareholder participation (including deadlines for registration and proxy submission), and a detailed agenda (DAGORDNING) covering items typical for an AGM, such as electing the board, auditors, approving financial statements, and proposing incentive programs. This content directly corresponds to the purpose of an Annual General Meeting notice and related materials. Therefore, the classification is AGM-R (AGM Information).
2024-03-21 Swedish
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)
AGM Information Classification · 100% confidence The document is explicitly titled "NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)". It details the date, time, and location of the meeting, the procedures for shareholder notification, proxy voting, and presents the proposed agenda items. The agenda includes items typical for an AGM, such as election of the Chairman, Board members, auditor, approval of remuneration reports, and resolutions on capital structure (share issues/warrants). This content perfectly matches the definition of materials shared during an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2024-03-21 English
Earnings Release 2023
Earnings Release Classification · 95% confidence The document is titled "Bokslutskommuniké 2023" (Year-end report/Financial Report 2023) and contains detailed financial figures for the fourth quarter and the full year (1 januari – 31 december 2023), including Net Sales, Gross Margin, EBIT, EBITDA, and Net Income, presented in a structured format with key performance indicators (Nyckeltal) and management commentary. This structure is characteristic of a comprehensive annual financial disclosure, which aligns best with the definition of an Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR). Since it covers the full fiscal year and is explicitly a 'Bokslutskommuniké' (Year-end communication), it is the annual disclosure. Although it might be a press release summarizing the 10-K, its depth and focus on the full year's performance strongly suggest it is the primary annual financial report or its direct equivalent in this context. Given the options, '10-K' is the closest match for a comprehensive annual financial report, even if the source language is Swedish. FY 2023
2024-01-25 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.